Phase 1 Study of the Safety and Immunogenicity of MSP1 42-C1/Alhydrogel With and Without CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria.

Trial Profile

Phase 1 Study of the Safety and Immunogenicity of MSP1 42-C1/Alhydrogel With and Without CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria.

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jan 2010

At a glance

  • Drugs Agatolimod (Primary) ; Aluminium hydroxide; Malaria vaccine
  • Indications Malaria
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 18 Jan 2008 Status change from recruiting to completed, from clinicaltrials.gov record.
    • 12 Jul 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top